Intellectual property

TL-532 and a new family of TLR3 ligands were patented by TOLLYS in 2018 (EP 18305561).
Logo Tollys

Tollys

A new dimension in immuno-oncology

Office

41 quai Fulchiron
69005 Lyon, FRANCE

Contact us